U.S. Consumer Product Safety Commission

LOG OF TELECONFERENCE

SUBJECT: Chronic Hazard Advisory Panel (CHAP) on Phthalates and Phthalate Substitutes

DATE: April 10, 2012

TIME: 11:00 a.m. to 12:45 p.m. EDT

ENTRY SOURCE: Michael A. Babich, HS

COMMISSION REPRESENTATIVES: Michael Babich, Kent Carlson (HS), Leslie Patton (HS), Kristina Hatlelid (HS); Mary Ann Danello (HS), Lori Saltzman (HS); David DiMatteo (GC), Cheryl Falvey (GC).

CHAP Members: Philip Mirkes (Chair), Chris Gennings, Russ Hauser, Holger Koch, Andreas Kortenkamp, Paul Lioy

NON CPSC REPRESENTATIVES: Members of the public were able to listen to the conference call. The names of individuals who requested dial-in instructions are attached.

SUMMARY:

This was the fifth teleconference of the Chronic Hazard Advisory Panel (CHAP) on Phthalates and Phthalate Substitutes. The CHAP previously met seven times in person since April 2010 at CPSC headquarters in Bethesda, MD.

Dr. Mirkes reviewed writing assignments for completing the draft report. The CHAP reviewed the existing portions of the report, and made suggestions for revisions. Most of the meeting was spent discussing the recommendations section. CPSC requested the addition of certain details and clarifications.

The CHAP reviewed its draft recommendations to the Commission. The CHAP’s recommendations will not be final until the final report is released. The CHAP is considering recommendations to prohibit certain antiandrogenic phthalates from use in children’s toys and child care articles, including diisobutyl phthalate (DIBP), di-n-pentyl phthalate, dicyclohexyl phthalate, and di-n-hexyl phthalate. The CHAP is considering a recommendation to prohibit diisooctyl phthalate (DIOP) on an interim basis until additional data are obtained regarding its antiandrogenic effects. The CHAP is also considering a recommendation to permanently prohibit DINP, which is currently subject to an interim ban. The CHAP also discussed whether the additional phthalates would be prohibited at the 0.1 percent level or another level.

The CHAP then discussed di-n-octyl phthalate (DNOP) and diisodecyl phthalate (DIDP), which are currently subject to an interim ban. These phthalates are not associated with the antiandrogenic effects of certain other phthalate. However, the CHAP will consider
other health endpoints before discussing whether to lift the interim ban on these phthalates.

The CHAP will schedule a conference call in the near future to complete its discussion on DNOP and DIDP and to discuss recommendations for phthalate substitutes. The phthalate substitutes are not associated with antiandrogenic effects and, therefore, the CHAP will consider other health endpoints for the phthalate substitutes.

Attachment:
- List of registrants

Additional Information is available at: http://www.cpsc.gov/about/cpsia/chapmain.html